###begin article-title 0
A functional variant of Fcgamma receptor IIIA is associated with rheumatoid arthritis in individuals who are positive for anti-glucose-6-phosphate isomerase antibodies
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 552 558 536 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 570 576 554 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 695 700 679 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 725 731 709 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 743 749 727 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 1112 1118 1096 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 1318 1324 1302 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 1385 1387 1369 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1682 1684 1666 1668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1697 1699 1681 1683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 164 170 <span type="species:ncbi:9606">humans</span>
###xml 898 906 <span type="species:ncbi:9606">patients</span>
###xml 1584 1589 <span type="species:ncbi:9606">human</span>
###xml 1599 1605 <span type="species:ncbi:9986">rabbit</span>
###xml 1625 1633 <span type="species:ncbi:9606">patients</span>
Anti-glucose-6-phosphate isomerase (GPI) antibodies are known to be arthritogenic autoantibodies in K/BxN mice, although some groups have reported that few healthy humans retain these antibodies. The expression of Fcgamma receptors (FcgammaRs) is genetically regulated and has strong implications for the development of experimental arthritis. The interaction between immune complexes and FcgammaRs might therefore be involved in the pathogenesis of some arthritic conditions. To explore the relationship between functional polymorphisms in FcgammaRs (FCGR3A-158V/F and FCGR2A-131H/R) and arthritis in individuals positive for anti-GPI antibodies, we evaluated these individuals with respect to FCGR genotype. Genotyping for FCGR3A-158V/F and FCGR2A-131H/R was performed by PCR amplification of the polymorphic site, followed by site specific restriction digestion using the genome of 187 Japanese patients with rheumatoid arthritis (including 23 who were anti-GPI antibody positive) and 158 Japanese healthy individuals (including nine who were anti-GPI antibody positive). We report here on the association of FCGR3A-158V/F functional polymorphism with anti-GPI antibody positive status. Eight out of nine healthy individuals who were positive for anti-GPI antibodies possessed the homozygous, low affinity genotype FCGR3A-158F (odds ratio = 0.09, 95% confidence interval 0.01-0.89; P = 0.0199), and probably were 'protected' from arthritogenic antibodies. Moreover, among those who were homozygous for the high affinity genotype FCGR3A-158V/V, there were clear differences in anti-human and anti-rabbit GPI titres between patients with rheumatoid arthritis and healthy subjects (P = 0.0027 and P = 0.0015, respectively). Our findings provide a molecular model of the genetic regulation of autoantibody-induced arthritis by allele-specific affinity of the FcgammaRs.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
Rheumatoid arthritis (RA) is a heterogeneous autoimmune disease that is characterized by chronic inflammatory polyarthritis [1]. One of the characteristic features of RA is the expression of several autoantibodies. The presence of such autoantibodies (e.g. rheumatoid factor [RF]), identified by screening, is commonly used as a diagnostic marker, although the pathogenic role played by autoantibodies in RA remains a mystery.
###end p 4
###begin p 5
###xml 395 396 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 397 398 369 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 582 588 542 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 590 604 550 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A, FCGR2C</italic>
###xml 606 613 566 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 617 623 577 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
###xml 884 885 832 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 886 887 834 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 924 930 872 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 1008 1009 956 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1010 1011 958 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1081 1083 1029 1031 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1101 1102 1045 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1171 1172 1115 1116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1211 1213 1155 1157 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1285 1292 1225 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 1444 1445 1384 1385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1446 1448 1386 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 162 168 <span type="species:ncbi:9606">humans</span>
###xml 213 218 <span type="species:ncbi:10090">mouse</span>
###xml 486 492 <span type="species:ncbi:9606">humans</span>
Fcgamma receptors (FcgammaRs) play a pivotal role in the reaction between immune complex and myeloid cells. Three FcgammaR types have been identified in mice and humans (FcgammaRI, FcgammaRII and FcgammaRIII). In mouse arthritis models, FcgammaRIII deficient hosts exhibit resistance to collagen type II induced arthritis and anti-glucose-6-phosphate isomerase (GPI) antibody induced arthritis [2,3], suggesting that FcgammaRIII is indispensible in autoantibody dependent arthritis. In humans FcgammaRs are encoded by eight genes, and the genes encoding the low affinity FcgammaRs (FCGR2A, FCGR3A, FCGR2C, FCGR3B and FCGR2B) are located within a gene cluster on chromosome 1q22-23. Of these FcgammaRs, FcgammaRIIIa and FcgammaRIIa are known to be stimulatory receptors. Various genetic polymorphisms of these receptors were reported to be associated with several autoimmune diseases [4,5], one of which is a polymorphism in FCGR3A, with either a phenylalanine (F) or a valine (V) at amino acid position 158 [6,7]. Moreover, based on findings from a co-crystalization study with IgG1 and FcgammaRIIIa [8], this residue directly interacts with the lower hinge region of IgG1, suggesting strong binding between IgG1 and FcgammaRIIIa-158V on both natural killer cells and macrophages. For FCGR2A genes, a polymorphism at position 131 (with either histidine [H] or arginine [R]) alters the ability of the receptor to bind to certain IgG subclasses [9,10].
###end p 5
###begin p 6
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCG3A</italic>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
In RA patients, FCG3A-158V/F polymorphisms were reported to be frequent in UK Caucasian, North Indian and Pakistani individuals [11,12], but not in Japanese, Spanish and French individuals [13-15]. The reason for these differences between populations is unknown, although it is possible that they might depend on the prevalence in these populations of patients with autoantibody related forms of RA, in particular the prevalence of those who have pathogenic autoantibodies that directly interact with FcgammaRs (especially FcgammaRIIIa).
###end p 6
###begin p 7
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 267 268 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 294 296 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 593 595 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 596 598 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 751 753 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 811 817 803 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 902 904 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 973 980 965 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 1086 1088 1078 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1089 1091 1081 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 69 73 <span type="species:ncbi:10090">mice</span>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
###xml 207 211 <span type="species:ncbi:10090">mice</span>
###xml 485 490 <span type="species:ncbi:9606">human</span>
###xml 548 556 <span type="species:ncbi:9606">patients</span>
###xml 1249 1254 <span type="species:ncbi:9606">human</span>
Anti-GPI antibodies are candidate arthritogenic antibodies. In K/BxN mice, polyclonal or two monoclonal anti-GPI antibodies induced arthritis in several strains of mice [16]. Moreover, FcgammaRIII deficient mice were resistant to anti-GPI antibody induced arthritis [3]. Another recent report [17] also confirmed that immune complex and FcgammaRIII are essential initiators of arthritis through sequential activation of effector cells, thus giving antibodies access into the joint. In human RA, anti-GPI antibodies have frequently been detected in patients with aggressive forms of arthritis [18,19], and their levels correlated significantly with extra-articular manifestations such as rheumatoid nodules, rheumatoid vasculitis and Felty's syndrome [20]. Moreover, a modest association of homozygosity for the FCGR3A-158V allele with RA in the nodular phenotype was suggested by Morgan and coworkers [11], suggesting the presence of a link between anti-GPI antibodies and FCGR3A allele. However, whether anti-GPI antibody positive status correlates with RA is a matter of controversy [18-22]. In our assay few healthy individuals retained anti-GPI antibodies; however, we do not know whether these protective phenotypes are associated with certain human gene polymorphisms.
###end p 7
###begin p 8
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 130 135 <span type="species:ncbi:9606">human</span>
In order to determine the relationship between functional polymorphisms of FCGR and possible arthritogenic anti-GPI antibodies in human conditions, we examined the correlation of these polymorphisms with anti-GPI positivity.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 10
###begin p 11
###xml 566 568 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 111 123 <span type="species:ncbi:9606">participants</span>
###xml 172 180 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
The study was approved by the local ethics review committee and written informed consent was obtained from all participants. Blood samples were collected from 187 Japanese patients with RA (mean age 46 +/- 17 years; 33 females; mean disease duration 12.9 years [range 1-46 years]) including four with vasculitis and three with Felty's syndrome. These patients, randomly selected from among patients visiting the clinic, were followed at University of Tsukuba Hospital. The diagnosis of RA was based on the criteria presented by the American College of Rheumatology [23]. In addition, 158 Japanese volunteers (mean age 30 +/- 9 years; 105 females) were recruited from our institute to serve as a healthy comparison group. All healthy individuals were free of rheumatic disease symptoms, and derived from the same geographic locations.
###end p 11
###begin title 12
Enzyme-linked immunosorbent assay for GPI
###end title 12
###begin p 13
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 925 926 906 907 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
###xml 76 81 <span type="species:ncbi:9606">human</span>
###xml 127 133 <span type="species:ncbi:9986">rabbit</span>
###xml 655 660 <span type="species:ncbi:9606">human</span>
###xml 1265 1270 <span type="species:ncbi:9606">human</span>
###xml 1453 1459 <span type="species:ncbi:9986">rabbit</span>
###xml 1774 1779 <span type="species:ncbi:9606">human</span>
###xml 1809 1815 <span type="species:ncbi:9986">rabbit</span>
In order to select anti-GPI antibody positive patients, we used recombinant human GPI (described in detail previously [18]) or rabbit muscle GPI (Sigma, St Louis, MO, USA). Both antigens were used at 5 mug/ml (diluted in phosphate-buffered saline [PBS]) to coat microtitre plates (12 hours, 4degreesC). After washing twice with washing buffer (0.05% Tween 20 in PBS), Block Ace (diluted 1/4 in 1 x PBS; Dainippon Pharmaceuticals, Osaka, Japan) was used for saturation (30 min at 37degreesC). After two washes, sera (diluted 1/50) were added and the plates were incubated for 12 hours at 4degreesC. After washing, alkaline phosphatase (AP)-conjugated anti-human IgG (Fc fragment specific; Jackson Immuno Research, West Grove, PA, USA) was added to the plate (dilution 1/1000, for 1 hour at room temperature). After three washes, colour was developed with AP reaction solution (containing 9.6% diethanol amine, 0.25 mmol/l MgCl2; pH 9.8) with AP substrate tablets (Sigma; one AP tablet per 5 ml AP reaction solution). Plates were incubated for 1 hour at room temperature, and the optical density (OD) was measured by plate spectrophotometry at 405 nm. Determinations were performed in triplicate and standardized between experiments by reference to a highly positive human anti-GPI serum. The primary reading was processed by subtracting OD readings of control wells (coated with gluthathione-S-transferase (GST) and Block Ace for recombinant GPI-GST and rabbit GPI, respectively). The cutoff OD was calculated from the ELISA reactions of 158 healthy Japanese donors. Those who were double positive to both antigens were considered anti-GPI antibody positive. Because we used two antigens for the discrimination, the cutoff OD (mean value + 1 standard deviation) was 0.98 for human recombinant GPI and 0.64 for rabbit native GPI.
###end p 13
###begin p 14
###xml 229 235 225 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 298 299 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 655 657 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 412 420 <span type="species:ncbi:9606">patients</span>
###xml 584 592 <span type="species:ncbi:9606">patients</span>
Genomic DNA was isolated from 0.5 ml anticoagulated peripheral blood, from 187 RA patients and 158 healthy individuals, by using DNA QuickII DNA purification kit (Dainippon Pharmaceuticals, Osaka, Japan). FcgammaR polymorphisms (FCGR3A-158V/F) were identified, as described by Koene and coworkers [6], using a nested PCR followed by allele specific restriction enzyme digestion. For homozygous FcgammaRIIIA-158F patients only one undigested band (94 bp) was visible. Three bands (94 bp, 61 bp and 33 bp) were seen in heterozygous individuals, whereas for homozygous FcgammaRIIIA-158V patients only two digested bands (61 bp and 33 bp) were detected (Fig. 1a). These genotyping findings were confirmed by direct sequencing in some individuals.
###end p 14
###begin title 15
FcgammaRIIA-131H/R genotyping
###end title 15
###begin p 16
###xml 179 181 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 188 194 184 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 204 210 200 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 295 297 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
Genotyping of FcgammaRIIA-131H/R also consisted of PCR followed by an allele specific restriction enzyme digestion, in accordance with the method reported by Jiang and coworkers [24]. The FCGR2A-131H and FCGR2A-131R alleles were visualized as 337 bp and 316 bp DNA fragments, respectively (Fig. 1b). These genotyping findings were confirmed by direct sequencing in some individuals.
###end p 16
###begin title 17
Statistical analysis
###end title 17
###begin p 18
###xml 43 44 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 61 63 59 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 287 289 281 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
The data were analyzed using the Student's t-test and the chi2 test, and Fisher's exact test was used when expected frequencies were lower than 5. We used Mann-Whitney U-test to evaluate the distribution of anti-GPI antibodies in FcgammaRIIIA-158V/V RA patients and healthy individuals. P < 0.05 was considered statistically significant.
###end p 18
###begin title 19
Results
###end title 19
###begin p 20
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 654 655 654 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 793 795 791 793 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 832 834 830 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 73 78 <span type="species:ncbi:9606">human</span>
###xml 94 100 <span type="species:ncbi:9986">rabbit</span>
###xml 538 546 <span type="species:ncbi:9606">patients</span>
###xml 756 764 <span type="species:ncbi:9606">patients</span>
Our ELISA assay is highly specific because we used recombinant bacterial human GPI and native rabbit GPI, and double positivity for the two antibodies correlated significantly with the results of western blotting to GPI [18]. Because two GPI antigens were used for discrimination, the cutoff value of the OD was the mean value + one standard deviation from 158 healthy individuals, estimated using ELISA. Those who were positive for both antibodies were considered to be anti-GPI antibody positive. Using these definitions, 23 (12.3%) RA patients were anti-GPI antibody positive, and nine (5.7%) healthy individuals were anti-GPI antibody positive (Fig. 2). Statistical analysis revealed a significant difference in anti-GPI antibody positivity between RA patients and healthy individuals (chi2 = 4.438, with one degree of freedom; P = 0.0352).
###end p 20
###begin p 21
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 153 160 153 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 164 171 164 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 242 248 242 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 418 420 416 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 457 459 455 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 475 476 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 481 482 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 694 700 692 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 816 822 814 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 879 881 875 877 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 916 918 912 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 933 934 929 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 939 940 935 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 957 963 953 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 1154 1160 1150 1156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 1276 1282 1272 1278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 1339 1341 1333 1335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1376 1378 1370 1372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1393 1394 1387 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 320 328 <span type="species:ncbi:9606">patients</span>
###xml 629 637 <span type="species:ncbi:9606">patients</span>
###xml 767 775 <span type="species:ncbi:9606">patients</span>
###xml 997 1005 <span type="species:ncbi:9606">patients</span>
###xml 1089 1097 <span type="species:ncbi:9606">patients</span>
###xml 1227 1235 <span type="species:ncbi:9606">patients</span>
To analyze whether functional FCGR polymorphisms were correlated with anti-GPI antibody positive and negative individuals, we performed FCGR genotyping. FCGR3A and FCGR2A genotypes in the control group were in Hardy-Weinberg equilibrium. The FCGR3A-158V allele (high affinity genotype) was more frequently identified in patients with RA than in healthy individuals within the anti-GPI antibody positive population (chi2 = 0.012, with one degree of freedom; P = 0.012; Tables 1 and 2). In addition, these differences were evident when individuals were categorized according to the presence or absence of these genotypes: 56.5% of patients with RA were homozygous or heterozygous with respect to FCGR3A-158V, as compared with 11.1% of healthy individuals; and 43.5% of patients with RA were homozygous with respect to FCGR3A-158F, as compared with 88.9% of healthy individuals (chi2 = 5.42 with one degree of freedom; P < 0.02; Tables 1 and 2). Comparison of FCGR3A-158V allele frequency between RA patients and healthy individuals revealed no statistically significant difference: 48.7% of patients with RA were homozygous or heterozygous with respect to FCGR3A-158V, as compared with 42.4% of healthy individuals; and 51.3% of patients with RA were homozygous with respect to FCGR3A-158F, as compared with 57.6% of healthy individuals (chi2 = 1.04 with one degree of freedom; P = 0.245; Table 1).
###end p 21
###begin p 22
###xml 6 13 6 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 83 89 83 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 264 266 262 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 302 304 300 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 320 320 318 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1"/>
###xml 325 326 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 460 462 458 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 477 478 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 483 484 481 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Next, FCGR2A genotyping was conducted in the same cohort (Table 1). In contrast to FCGR3A, the frequency of the FCGR2A-131H allele (high affinity genotype) was not significantly different between the two groups within the anti-GPI antibody positive population (chi2 = 0.862 with one degree of freedom; P = 0.35; Tables 1 and 2). These differences were also not evident when individuals were categorized according to the presence or absence of these genotypes (P = 0.19; Tables 1 and 3).
###end p 22
###begin p 23
###xml 183 185 179 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 196 198 192 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 208 215 204 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 219 225 215 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 247 248 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
We also analyzed the association between FcgammaR and other related autoantibodies such as RF. There was no difference between RF positive and RF negative populations of RA patients (P = 0.82 and P = 0.4 for FCGR3A and FCGR2A, respectively; Table 4).
###end p 23
###begin p 24
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 180 186 180 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 416 418 416 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 431 433 431 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 547 548 547 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 637 643 637 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 319 324 <span type="species:ncbi:9606">human</span>
###xml 349 355 <span type="species:ncbi:9986">rabbit</span>
###xml 451 456 <span type="species:ncbi:9606">human</span>
###xml 481 487 <span type="species:ncbi:9986">rabbit</span>
Finally, in order to identify the relationship between FCGR3A-158V allele and anti-GPI antibodies more clearly, we focused on individuals who were homozygous for the high affinity FCGR3A-158V/V genotype (14 RA patients and eight healthy individuals) and compared their anti-GPI antibody titres. Surprisingly, both anti-human GPI antibodies and anti-rabbit GPI antibodies were significantly elevated in the RA group (P = 0.0027 and P = 0.0015 for anti-human GPI antibodies and anti-rabbit GPI antibodies, respectively, by Mann-Whitney U-test; Fig. 3). This suggests that anti-GPI antibody positivity might predispose individuals with the FCGR3A-158V/V genotype to arthritis.
###end p 24
###begin title 25
Discussion
###end title 25
###begin p 26
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 651 653 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 851 853 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 144 152 <span type="species:ncbi:9606">patients</span>
###xml 475 480 <span type="species:ncbi:10090">mouse</span>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
###xml 636 641 <span type="species:ncbi:10090">mouse</span>
Several studies have indicated that anti-GPI antibodies are potential arthritogenic antibodies [18-20] because they were frequently detected in patients with severe forms of RA. Because high titres of these antibodies (IgG, not IgM) were also detected in healthy individuals, the arthritogenicity of these antibodies should be due to modulation - by the low affinity genotype of FcgammaRs - of the bypass between immune complex and FcgammaR bearing cells. In a GPI immunized mouse model severe arthritis occurred only in DBA/1 mice, although the production of anti-GPI antibodies was almost equal in arthritis susceptible and resistant mouse strains [25]. Thus, the incidence of arthritis might depend on certain genetic factors such as FcgammaR. Anti-GPI antibody positive individuals express several GPI variant mRNAs in peripheral blood monocytes [26]. This observation supports the notion that the presence of GPI variants is necessary to produce anti-GPI autoantibodies, and that genetic factors such as FcgammaRIIIA are important in the development of arthritis. Based on this conclusion, it is conceivable that the production of anti-GPI antibodies does not occur as a 'result' of joint destruction.
###end p 26
###begin p 27
###xml 65 72 65 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 76 83 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 173 178 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 371 372 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 397 403 397 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 610 616 610 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 479 487 <span type="species:ncbi:9606">patients</span>
Our results do not indicate that individual polymorphisms in the FCGR3A and FCGR2A genes play roles in susceptibility to RA. Despite the lack of association with individual FCGR polymorphisms in the whole cohort, our studies suggest that FCGR3A-158V/F polymorphisms play a crucial role in RA among those individuals who are positive for anti-GPI antibodies (Tables 2 and 3). Moreover, focusing on FCGR3A-158V/V homozygous individuals, anti-GPI antibodies were clearly evident in patients with RA. These findings suggest that anti-GPI antibodies might have arthritogenic potential in individuals homozygous for FCGR3A-158V/V.
###end p 27
###begin title 28
Conclusion
###end title 28
###begin p 29
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
Our findings show that FCGR3A-158V/F functional polymorphisms were associated with RA among anti-GPI antibody positive individuals. This is the first report on possible mechanisms of arthritic diseases; they are tightly regulated by some genes, especially by FcgammaR genotype, as well as by production of arthritogenic autoantibodies.
###end p 29
###begin title 30
Abbreviations
###end title 30
###begin p 31
AP = alkaline phosphatase; bp = base pairs; ELISA = enzyme-linked immunosorbent assay; FcgammaR = Fcgamma receptor; GPI = glucose-6-phosphate isomerase; GST = gluthathione-S-transferase; OD = optical density; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; RA = rheumatoid arthritis; RF = rheumatoid factor.
###end p 31
###begin title 32
Competing interests
###end title 32
###begin p 33
The author(s) declare that they have no competing interests.
###end p 33
###begin title 34
Authors' contributions
###end title 34
###begin p 35
IM wrote the manuscript and conceived the study. HZ performed FcgammaR genotyping and coordinated the statistical analysis. YM, TY and YK performed GPI ELISA. TH participated in clinical assessment. TS participated in the full design and coordination of the study, and DG, SI and AT participated in writing the discussion.
###end p 35
###begin title 36
Acknowledgements
###end title 36
###begin p 37
This work was supported in part by the Japanese Ministry of Science and Culture (IM, TS). IM is also a recipient of a fellowship from the Japan Intractable Diseases Research Foundation, Uehara Memorial Foundation, and Japan Rheumatoid Foundation.
###end p 37
###begin article-title 38
Evolving concepts of rheumatoid arthritis
###end article-title 38
###begin article-title 39
Expression of FcgammaRIII is required for development of collagen-induced arthritis
###end article-title 39
###begin article-title 40
Arthritis critically dependent on innate immune system players
###end article-title 40
###begin article-title 41
Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse
###end article-title 41
###begin article-title 42
Immunoglobulin G Fc-receptor (FcgammaR) IIA and IIIB polymorphisms related to disability in MS
###end article-title 42
###begin article-title 43
Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype
###end article-title 43
###begin article-title 44
A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease
###end article-title 44
###begin article-title 45
###xml 35 40 <span type="species:ncbi:9606">human</span>
The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex
###end article-title 45
###begin article-title 46
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 99 104 <span type="species:ncbi:9606">human</span>
A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding
###end article-title 46
###begin article-title 47
###xml 83 88 <span type="species:ncbi:9606">human</span>
###xml 169 174 <span type="species:ncbi:9606">human</span>
On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2
###end article-title 47
###begin article-title 48
Fcgamma receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups
###end article-title 48
###begin article-title 49
FcgammaRIIIA-158V and rheumatoid arthritis: a confirmation study
###end article-title 49
###begin article-title 50
Studies on the association of Fc gamma receptor IIA, IIB, IIIA and IIIB polymorphisms with rheumatoid arthritis in the Japanese: evidence for a genetic interaction between HLA-DRB1 and FCGR3A
###end article-title 50
###begin article-title 51
Role of Fcgamma receptors IIA, IIIA, and IIIB in susceptibility to rheumatoid arthritis
###end article-title 51
###begin article-title 52
Involvement of Fcgamma receptor IIIA genotypes in susceptibility to rheumatoid arthritis
###end article-title 52
###begin article-title 53
Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme
###end article-title 53
###begin article-title 54
Dynamic visualization of a joint-specific autoimmune response through positron emission tomography
###end article-title 54
###begin article-title 55
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders
###end article-title 55
###begin article-title 56
###xml 83 88 <span type="species:ncbi:9606">human</span>
Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease
###end article-title 56
###begin article-title 57
Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis
###end article-title 57
###begin article-title 58
###xml 4 9 <span type="species:ncbi:9606">human</span>
Few human autoimmune sera detect GPI
###end article-title 58
###begin article-title 59
Autoantibodies to GPI and creatine kinase in RA
###end article-title 59
###begin article-title 60
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
###end article-title 60
###begin article-title 61
Rapid detection of the Fc gamma RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED)
###end article-title 61
###begin article-title 62
###xml 123 127 <span type="species:ncbi:10090">mice</span>
Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice
###end article-title 62
###begin article-title 63
Glucose-6-phosphate isomerase variants play a key role in the generation of anti-GPI antibodies: possible mechanism of autoantibody production
###end article-title 63
###begin title 64
Figures and Tables
###end title 64
###begin p 65
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 36 43 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 195 199 195 199 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 199 206 199 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 215 219 215 219 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 219 226 219 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
PCR-RFLP analysis of the FCGR3A and FCGR2A genes. cDNA was amplified with primers and restriction digested using appropriate enzymes. Digested PCR products were visualized with ethidium bromide. (a) FCGR3A gene and (b) FCGR2A gene. ND, nondigested PCR product; RE, restriction enzyme.
###end p 65
###begin p 66
###xml 58 65 58 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 69 76 69 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 331 336 <span type="species:ncbi:9606">human</span>
###xml 357 363 <span type="species:ncbi:9986">rabbit</span>
Population of anti-GPI antibody positive individuals, and FCGR3A and FCGR2A genotypes. The study included 187 patients with rheumatoid arthritis and 158 healthy Japanese individuals. The horizontal and vertical dotted lines represent the cutoff optical density values calculated from ELISA reactions of 158 healthy individuals for human recombinant GPI and rabbit native GPI, respectively. Individuals positive for both antibodies were considered anti-GPI antibody positive. Numbers in each graph represent the proportions of individuals positive for anti-GPI antibodies relative to the total number of individuals in that group. GPI, glucose-6-phosphate isomerase; HS, healthy subjects; RA, rheumatoid arthritis.
###end p 66
###begin p 67
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 150 157 150 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 335 337 335 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 350 352 350 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 37 43 <span type="species:ncbi:9986">rabbit</span>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 238 243 <span type="species:ncbi:9606">human</span>
###xml 268 274 <span type="species:ncbi:9986">rabbit</span>
###xml 370 375 <span type="species:ncbi:9606">human</span>
###xml 400 406 <span type="species:ncbi:9986">rabbit</span>
Higher titres of anti-human and anti-rabbit GPI antibodies in FCGR3A-158V/V RA patients versus healthy individuals. In individuals homozygous for the FCGR3A high affinity V/V genotype (14 RA patients and 8 healthy individuals), both anti-human GPI antibodies and anti-rabbit GPI antibodies were significantly elevated in the RA group (P = 0.0027 and P = 0.0015 for anti-human GPI antibodies and anti-rabbit GPI antibodies, respectively, by Mann-Whitney U-test). GPI, glucose-6-phosphate isomerase; RA, rheumatoid arthritis.
###end p 67
###begin p 68
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Frequencies of FCGR3A and FCGR2A genotypes in patients with RA and positive and negative for anti-GPI antibodies
###end p 68
###begin p 69
Data are expressed as number (percentage) of individuals. GPI, glucose-6-phosphate isomerase; high, high affinity genotype; low, low affinity genotype; RA, rheumatoid arthritis.
###end p 69
###begin p 70
###xml 18 25 18 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
Alleic skewing of FCGR3A and FCGR2A in anti-GPI antibody positive healthy individuals
###end p 70
###begin p 71
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
P values are given for RA versus healthy individuals using a 2x2 contingency table. CI, confidence interval; Fisher's, Fisher's probability test; OR, odds ratio; RA, rheumatoid arthritis.
###end p 71
###begin p 72
###xml 20 27 20 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 31 38 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
Genotype skewing of FCGR3A and FCGR2A gene polymorphisms in anti-GPI antibody positive healthy individuals
###end p 72
###begin p 73
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
P values are given for RA versus healthy individuals using a 2x2 contingency table. CI, confidence interval; Fisher's, Fisher's probability test; OR, odds ratio; RA, rheumatoid arthritis.
###end p 73
###begin p 74
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 11 18 11 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
FCGR3A and FCGR2A genotypes in rheumatoid factor positive and negative RA patients
###end p 74
###begin p 75
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 28 30 28 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
P values are given for RA RF+ versus RA RF- using a 2x2 contingency table. CI, 95% confidence interval; OR, odds ratio; RA, rheumatoid arthritis; RF, rheumatoid factor.
###end p 75

